Immunotherapy at all stages of hepatocellular carcinoma

被引：10

作者：

Pinato, David J. ^{[1
,2
]}

Fulgenzi, Claudia A. M. ^{[1
]}

D'Alessio, Antonio ^{[1
,2
]}

机构：

[1] Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus, London, England

[2] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy

来源：

NATURE MEDICINE | 2024年 / 30卷 / 03期

关键词：

CHEMOTHERAPY; BEVACIZUMAB;

D O I：

10.1038/s41591-024-02828-8

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A flurry of emerging treatment options is transforming the therapeutic landscape of hepatocellular carcinoma; two new studies highlight the complexities and gaps in knowledge, but also hint at a greater understanding of how to apply immunotherapy in early and advanced disease.

引用

页码：640 / 641

页数：2

共 7 条

[1] Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial [J].

de Gramont, Aimery ;

Van Cutsem, Eric ;

Schmoll, Hans-Joachim ;

Tabernero, Josep ;

Clarke, Stephen ;

Moore, Malcolm J. ;

Cunningham, David ;

Cartwright, Thomas H. ;

Hecht, J. Randolph ;

Rivera, Fernando ;

Im, Seock-Ah ;

Bodoky, Gyoergy ;

Salazar, Ramon ;

Maindrault-Goebel, Frederique ;

Shacham-Shmueli, Einat ;

Bajetta, Emilio ;

Makrutzki, Martina ;

Shang, Aijing ;

Andre, Thierry ;

Hoff, Paulo M. .

LANCET ONCOLOGY, 2012, 13 (12) :1225-1233

[2] T-cell invigoration to tumour burden ratio associated with anti-PD-1 response [J].

Huang, Alexander C. ;

Postow, Michael A. ;

Orlowski, Robert J. ;

Mick, Rosemarie ;

Bengsch, Bertram ;

Manne, Sasikanth ;

Xu, Wei ;

Harmon, Shannon ;

Giles, Josephine R. ;

Wenz, Brandon ;

Adamow, Matthew ;

Kuk, Deborah ;

Panageas, Katherine S. ;

Carrera, Cristina ;

Wong, Phillip ;

Quagliarello, Felix ;

Wubbenhorst, Bradley ;

D'Andrea, Kurt ;

Pauken, Kristen E. ;

Herati, Ramin S. ;

Staupe, Ryan P. ;

Schenkel, Jason M. ;

McGettigan, Suzanne ;

Kothari, Shawn ;

George, Sangeeth M. ;

Vonderheide, Robert H. ;

Amaravadi, Ravi K. ;

Karakousis, Giorgos C. . ;

Schuchter, Lynn M. ;

Xu, Xiaowei ;

Nathanson, Katherine L. ;

Wolchok, Jedd D. ;

Gangadhar, Tara C. ;

Wherry, E. John .

NATURE, 2017, 545 (7652) :60-+

[3] Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial [J].

Kim, Hyung-Don ;

Jung, Seyoung ;

Lim, Ho Yeong ;

Ryoo, Baek-Yeol ;

Ryu, Min-Hee ;

Chuah, Samuel ;

Chon, Hong Jae ;

Kang, Beodeul ;

Hong, Jung Yong ;

Lee, Han Chu ;

Moon, Deok-Bog ;

Kim, Ki-Hun ;

Kim, Tae Won ;

Tai, David ;

Chew, Valerie ;

Lee, Jeong Seok ;

Finn, Richard S. ;

Koh, June-Young ;

Yoo, Changhoon .

NATURE MEDICINE, 2024, 30 (03) :699-+

[4] Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial [J].

Qin, Shukui ;

Chen, Minshan ;

Cheng, Ann-Lii ;

Kaseb, Ahmed ;

Kudo, Masatoshi ;

Lee, Han Chu ;

Yopp, Adam C. ;

Zhou, Jian ;

Wang, Lu ;

Wen, Xiaoyu ;

Heo, Jeong ;

Tak, Won Young ;

Nakamura, Shinichiro ;

Numata, Kazushi ;

Uguen, Thomas ;

Hsiehchen, David ;

Cha, Edward ;

Hack, Stephen P. ;

Lian, Qinshu ;

Ma, Ning ;

Spahn, Jessica H. ;

Wang, Yulei ;

Wu, Chun ;

Chow, Pierce K. H. .

LANCET, 2023, 402 (10415) :1835-1847

[5] Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial [J].

Wakelee, Heather A. ;

Dahlberg, Suzanne E. ;

Keller, Steven M. ;

Tester, William J. ;

Gandara, David R. ;

Graziano, Stephen L. ;

Adjei, Alex A. ;

Leighl, Natasha B. ;

Aisner, Seena C. ;

Rothman, Jan M. ;

Patel, Jyoti D. ;

Sborov, Mark D. ;

McDermott, Sean R. ;

Perez-Soler, Roman ;

Traynor, Anne M. ;

Butts, Charles ;

Evans, Tracey ;

Shafqat, Atif ;

Chapman, Andrew E. ;

Kasbari, Samer S. ;

Horn, Leora ;

Ramalingam, Suresh S. ;

Schiller, Joan H. .

LANCET ONCOLOGY, 2017, 18 (12) :1610-1623

[6] Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial [J].

Wang, Kang ;

Xiang, Yan-Jun ;

Yu, Hong-Ming ;

Cheng, Yu-Qiang ;

Liu, Zong-Han ;

Qin, Ying-Yi ;

Shi, Jie ;

Guo, Wei-Xing ;

Lu, Chong-De ;

Zheng, Ya-Xin ;

Zhou, Fei-Guo ;

Yan, Mao-Lin ;

Zhou, Hong-Kun ;

Liang, Chao ;

Zhang, Fan ;

Wei, Wen-Jing ;

Lau, Wan Yee ;

Li, Jing-Jing ;

Liu, Yan-Fang ;

Cheng, Shu-Qun .

NATURE MEDICINE, 2024, 30 (03) :708-+

[7] Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma [J].

Zhu, Andrew X. ;

Abbas, Alexander R. ;

de Galarreta, Marina Ruiz ;

Guan, Yinghui ;

Lu, Shan ;

Koeppen, Hartmut ;

Zhang, Wenjun ;

Hsu, Chih-Hung ;

He, Aiwu Ruth ;

Ryoo, Baek-Yeol ;

Yau, Thomas ;

Kaseb, Ahmed O. ;

Burgoyne, Adam M. ;

Dayyani, Farshid ;

Spahn, Jessica ;

Verret, Wendy ;

Finn, Richard S. ;

Toh, Han Chong ;

Lujambio, Amaia ;

Wang, Yulei .

NATURE MEDICINE, 2022, 28 (08) :1599-+

← 1 →